Relapsing MS Patients More Satisfied With Novartis Pharmaceuticals Corporation (NVS) Oral Drug Gilenya® Than Standard Injectable Therapies, According to New Study Results at Consortium Service Management Group (CTUM.OB)
5/30/2013 6:39:55 AM
More...
|
New Analysis Shows Novartis Pharmaceuticals Corporation (NVS) Drug Gilenya® Significantly Reduced Rate of Brain Volume Loss Across Three Large Phase III Studies
3/21/2013 10:34:29 AM
More...
|
Novartis Pharmaceuticals Corporation (NVS) Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
2/25/2013 10:38:43 AM
More...
|
The New England Journal of Medicine Published Study Shows Novartis Pharmaceuticals Corporation (NVS) Compound ACZ885 Significantly Relieves Symptoms in Patients With Serious Form of Childhood Arthritis
12/20/2012 8:36:58 AM
More...
|
Selexys Pharmaceuticals Corporation Completes $23 Million Equity Financing and Signs Agreement With Novartis Pharmaceuticals Corporation (NVS) for Up to $665 Million
9/19/2012 7:29:31 AM
More...
|
FDA Panel Backs Novartis Pharmaceuticals Corporation (NVS)'s Cystic Fibrosis Drug
9/6/2012 7:20:08 AM
More...
|
Novartis Pharmaceuticals Corporation (NVS) Drug RAD001 Plus Reduced Tacrolimus Provides Similar Efficacy and Better Renal Function Compared to Standard Tacrolimus, Study Shows
8/10/2012 11:23:54 AM
More...
|
Two New Analyses Reinforce Consistent Efficacy of Novartis Pharmaceuticals Corporation (NVS) Therapy Gilenya Across Wide Range of Relapsing MS Patients
5/31/2012 2:14:02 PM
More...
|
TV Host Phil Keoghan and Professional Women Cyclists Join Novartis Pharmaceuticals Corporation (NVS) to Raise Awareness of Multiple Sclerosis
5/8/2012 10:44:28 AM
More...
|
Novartis Pharmaceuticals Corporation (NVS) Expands Transplant Portfolio With Hecoria®, the First Generic Tacrolimus That Can be Prescribed by Brand Name
4/3/2012 11:12:11 AM
More...
|
|